April 26, 2017
Recommended Topic Related To:


" Editor's note: This story was updated on Dec. 30 with a CDC update.

Dec. 17, 2014 -- Flu season is in full force, according to the CDC, which is reporting widespread disease activity in 36 states for the wee"...





Included as part of the PRECAUTIONS section.


Guillain-Barré Syndrome

The 1976 swine influenza vaccine was associated with an elevated risk of Guillain-Barré syndrome (GBS). Evidence for a causal relation of GBS with other influenza vaccines is inconclusive; if an excess risk exists, it is probably slightly more than 1 additional case per 1 million persons vaccinated.1 If GBS has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX should be based on careful consideration of the potential benefits and risks.


The tip caps of the pre-filled syringes may contain natural rubber latex which may cause allergic reactions in latex-sensitive individuals. [see DESCRIPTION]

Preventing And Managing Allergic Reactions

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.


Syncope (fainting) can occur in association with administration of injectable vaccines, including Flucelvax. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope by maintaining a supine or Trendelenburg position.

Altered Immunocompetence

After vaccination with FLUCELVAX, immunocompromised individuals, including those receiving immunosuppressive therapy, may have a reduced immune response. [See Concurrent use with Immunosuppresive Therapies]

Limitations Of Vaccine Effectiveness

Vaccination with FLUCELVAX may not protect all vaccine recipients against influenza disease.


1. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998; 339(25):1797-1802.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment Of Fertility

FLUCELVAX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility in animals.

FLUCELVAX did not affect female fertility in a rabbit reproductive and developmental toxicity study.

Use In Specific Populations


Pregnancy Category B: A reproductive and developmental toxicity study has been performed in rabbits with a dose level that was approximately 15 times the human dose based on body weight. The study revealed no evidence of impaired female fertility or harm to the fetus due to FLUCELVAX. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this vaccine should be used during pregnancy only if clearly needed.

In a reproductive and developmental toxicity study, the effect of FLUCELVAX on embryo-fetal and post-natal development was evaluated in pregnant rabbits. Animals were administered FLUCELVAX by intramuscular injection 3 times prior to gestation, during the period of organogenesis (gestation day 7) and later in pregnancy (gestation day 20), 0.5 mL/rabbit/occasion (approximately 15-fold excess relative to the projected human dose on a body weight basis). No adverse effects on mating, female fertility, pregnancy, embryo-fetal development, or post-natal development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis.

Nursing Mothers

FLUCELVAX has not been evaluated in nursing mothers. It is not known whether FLUCELVAX is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when FLUCELVAX is administered to a nursing woman.

Pediatric Use

Safety and effectiveness have not been established in children less than 18 years of age.

Geriatric Use

Of the total number of subjects who received one dose of FLUCELVAX in clinical studies and included in the safety population (6281), 9% (572) were 65 years of age and older and 2% (140) were 75 years of age or older.

Antibody responses to FLUCELVAX were lower in the geriatric (adults 65 years and older) population than in younger subjects. [see Clinical Studies]

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 10/15/2015


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.